Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of artemisinin in preparation of drugs for resisting human liver cancer HepG2 and Huh7 cells
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An artemisinin and cell technology, applied in antitumor drugs, drug combinations, pharmaceutical formulations, etc., can solve the problems of difficulty in early detection of HCC and low survival rate of HCC patients
Inactive Publication Date: 2019-08-23
SOUTHERN MEDICAL UNIVERSITY
View PDF1 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Despite great achievements in novel therapeutics and diagnostic techniques, early detection of HCC is difficult, resulting in a low 5-year survival rate (0-14%) for HCC patients
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0053] The artemisinin medicine is made into granules, and the preparation method is as follows:
[0054] 1) Take 50g of artemisinin, add water and decoct twice, the first time for 2 hours, the second time for 1 hour, combine the decoction, filter, and concentrate the filtrate to an appropriate amount (about 50mL);
[0055] 2) Add ethanol to make the alcohol content 60%, stir while adding, let it stand for precipitation, take the supernatant to recover ethanol, concentrate to a clear paste with a relative density of 1.30-1.33 (80°C) (about 1:4, That is, 1 part of clear ointment is equivalent to 4 parts of medicinal materials);
[0056] 3) Add 20g of a mixture of sugarcane powder and dextrin (sucrose:dextrin=3:1) and 10ml of 70% ethanol, mix to form soft powder, squeeze and sieve (12-14 mesh) to make granules;
[0057] 4) Dried at 60°C, granulated, packed in plastic bags equivalent to 10 g of artemisinin per bag, and sealed to obtain artemisinin granules.
[0061] The artemisinin medicine is made into capsules, and the preparation method is as follows:
[0062] 1) Take 25 g of artemisinin and pulverize it into a coarse powder, reflux with 95% ethanol for 1 hour, and filter; then reflux the dregs with 50% ethanol for 1.5 hours, filter, combine the filtrates, and recover ethanol;
[0063] 2) Decoct the dregs with water for 2 hours, filter, combine the decoction and filtrate, and concentrate until syrupy;
[0064] 3) Add 10g of starch and mix well, add an appropriate amount of starchslurry, mix to make soft powder, press through a 80-100 mesh sieve to granulate, dry at 60-70°C, and granulate;
[0065] 4) Add 0.15 g of magnesiumstearate, mix well, and pack into capsules to obtain artemisinin capsules.
[0066] Administration method: Oral, 1 to 2 times a day, 1 to 2 capsules each time, suitable for consumption on an empty stomach. Those with sensitive stomachs, please take with meals.
[0067] Precautions: Keep out of reach of ch...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses application of artemisinin in preparation of drugs for resisting human livercancer HepG2 and Huh7 cells. The purpose is achieved by inhibiting proliferation of the human livercancer HepG2 and Huh7 cells, and / or adjusting the expression profile of miRNA in the human livercancer HepG2 and Huh7 cells. The concentration of the artemisinin is lower than or equal to 100 micromoles; the drugs are in an electuary dosage form or a capsuledosage form. The invention further discloses a drug electuary which contains the artemisinin and resists the human livercancer HepG2 and Huh7 cells, a drugcapsule which contains the artemisinin and resists the human liver cancer HepG2 and Huh7 cells and preparation method of the drugcapsule. Under the effect of the artemisinin drugs,the proliferation of the human liver cancer HepG2 and Huh7 cells is inhibited, changes of the expression profile of the miRNA in the human liver cancer HepG2 and Huh7 cells are adjusted and controlled, the miRNA potentially adjusting and controlling the liver cancer is discovered, and the foundation is laid for strategic development of the artemisinin in the aspect of liver cancer treatment.
Description
technical field [0001] The invention relates to the application of artemisinin in the preparation of anti-human liver cancer HepG2 and Huh7 cell medicines, belonging to the technical field of biopharmaceuticals. The medicine can inhibit the proliferation of human liver cancer HepG2 cells and Huh7 cells and regulate the miRNA expression profile of human liver cancer HepG2 cells and Huh7 cells. Background technique [0002] Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, accounting for 90% of primary liver cancers. Despite great achievements in novel therapeutics and diagnostic techniques, early detection of HCC is difficult, resulting in a low 5-year survival rate (0-14%) for HCC patients. Therefore, it is crucial to discover specific and sensitive biomarkers that can identify HCC. Artemisia annua is an important Chinese herbal medicine. Artemisinin, extracted from the herbArtemisia annua, is an active ingredient in antimalarial drugs. In recent...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
